

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

Form 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) July 28, 2026

THE ONCOLOGY INSTITUTE, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-39248
(Commission File Number)

84-3562323
(I.R.S. Employer
Identification No.)

18000 Studebaker Road, Suite 800, Cerritos, CA
(Address of principal executive offices)

90703
(Zip Code)

Registrant's telephone number, including area code: **(562) 735-3226**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value \$0.0001	TOI	The Nasdaq Stock Market LLC
Redeemable warrants, each whole warrant exercisable for one share of Common stock, each at an exercise price of \$11.50 per share	TOIIW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On July 28, 2026, The Oncology Institute, Inc., a Delaware corporation (the “Company”) filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Third Amended and Restated Certificate of Incorporation changing the Company’s name from “The Oncology Institute, Inc.” to “Starling Oncology, Inc.”, effective immediately. A copy of the Certificate of Amendment is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

Pursuant to Section 242 of the General Corporation Law of the State of Delaware, no stockholder approval was required for the Certificate of Amendment because it only related to a name change.

In connection with the name change, the Company’s trading symbol for its common stock begins trading on the Nasdaq Stock Market LLC on August 3, 2026, as “STLN”.

Neither the name change, nor the symbol change, affects the rights of the Company’s stockholders, and stockholders do not need to take any action in connection therewith. The CUSIP number for the Company’s common stock remains 68236X100.

Item 7.01 Regulation FD Disclosure

On August 3, 2026, the Company issued a press release announcing the name change and the symbol change from TOI to STLN. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished, shall not be deemed “filed” for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Securities Exchange Act of 1934, as amended (the “Exchange Act”), except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Description of Exhibit
3.1	Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation dated July 28, 2026
99.1	Press Release dated August 3, 2026
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 3, 2026

THE ONCOLOGY INSTITUTE, INC.

By: /s/ Minh Merchant

Name: Minh Merchant

Title: Chief Legal Officer

DocuSign Envelope ID: 2615BF0A-B479-87A5-8132-E6E4C838A103

State of Delaware
 Secretary of State
 Division of Corporations
 Delivered 12:11 PM 07/28/2026
 FILED 12:11 PM 07/28/2026
 SR 20263865748 - File Number 7682314

**STATE OF DELAWARE
 CERTIFICATE OF AMENDMENT
 OF CERTIFICATE OF INCORPORATION**

The corporation organized and existing under the General Corporation Law of the State of Delaware, hereby certifies as follows:

1. The name of the corporation is The Oncology Institute, Inc.

2. The Certificate of Incorporation of the corporation is hereby amended by changing the Article thereof numbered Article 1 so that, as amended, said Article shall be and read as follows:

The name of the corporation is Starling Oncology, Inc. (the "Corporation").

3. That said amendment was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.

By:  Daniel Virnich
 Authorized Officer

Name: Daniel Virnich, Chief Executive Officer
 Print or Type



The Oncology Institute Rebrands as Starling Oncology

Company to begin trading on Nasdaq under new ticker symbol "STLN," replacing "TOI"

CERRITOS, Calif., Aug. 3, 2026 (GLOBE NEWSWIRE) – The Oncology Institute, Inc. ("TOI" or "the Company"), one of the largest value-based oncology groups in the United States, announced today that it has rebranded to "Starling Oncology, Inc.™." The Company's common stock will begin trading under the new ticker symbol "STLN" on Nasdaq, effective August 4, 2026, replacing its previous ticker symbol "TOI."

"We've spent the past several years rebuilding this organization, reaching profitability, and scaling a technology-enabled, highly coordinated care model. We have proven that we have a better solution for both payers and the patients who trust us with accessible, outcomes-focused, high-quality medical care," said Dan Virnich, MD, MBA, FACHE, Chief Executive Officer of Starling Oncology. "Starling Oncology is a name that reflects our scale and our continued upward trajectory as an organization. Like starlings in flight, our coordinated delivery model emphasizes accessibility and teamwork that defines our commitment to community-based cancer care. Our name is changing, but our mission remains steadfast: delivering high-quality, patient-centered cancer care to the communities we serve, with a focused ambition to help solve the cost crisis in oncology."

The rebrand marks an important milestone in the Company's continued growth and reflects its evolution beyond a traditional oncology practice into an integrated oncology platform serving patients, providers, and health plans across multiple markets.

As the Company rebrands, patients, payers and providers can expect the same phone numbers, portal access, and points of contact throughout the transition, with no disruption to care.

About Starling Oncology:

Founded in 2007, Starling Oncology, Inc. (Nasdaq: STLN) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. Formerly known as The Oncology Institute, Starling Oncology offers cutting-edge, evidence-based cancer care to a population of approximately 2.1 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with leading oncology organizations. With more than 400 employed and network clinicians and more than 100 clinics and network locations across five states and growing, Starling Oncology is coordinating cancer care for the better. For more information, visit www.starlingoncology.com. Please follow us on LinkedIn, X (formerly Twitter), or Bluesky.

Contacts:

Media
ICR Healthcare
StarlingPR@icrhealthcare.com

Investors
ICR Healthcare
StarlingIR@icrhealthcare.com

+++